BR-Ibrutinib Regimen

**Semantic type:** Therapeutic or Preventive Procedure

**Definition:** A regimen consisting of ibrutinib, bendamustine and rituximab that may be used in the treatment of certain types of relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

**Synonyms:** - Bendamustine and Rituximab (BR) and Ibrutinib - Bendamustine and Rituximab-abbs (BR) and Ibrutinib - Bendamustine and Rituximab-arrx (BR) and Ibrutinib - Bendamustine and Rituximab-blit (BR) and Ibrutinib - Bendamustine and Rituximab-pvvr (BR) and Ibrutinib - Bendamustine and Rituximab-rite (BR) and Ibrutinib - Bendamustine and Rituximab-rixa (BR) and Ibrutinib - Bendamustine and Rituximab-rixi (BR) and Ibrutinib - Bendamustine/Ibrutinib/Rituximab - Ibrutinib-Bendamustine-Rituximab - Ibrutinib/Bendamustine + Rituximab - Ibrutinib/Bendamustine Plus Rituximab - Ibrutinib/Bendamustine/Rituximab - Ibrutinib/Bendamustine/Rituximab Regimen - Imbruvica/Treanda/Rituxan